You missed the point. Keep up.. Best bet is to trade with the big boys premarket in sell at open
Or buy after hours sell at premarket or open.
Flip in the case of last minute pr
Stop looking for a reason to argue
No one will listen to your rubbish
We don't need your explanation. Just say what you gotta say n leave it at that
Recent MNPR News
- Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients • GlobeNewswire Inc. • 04/10/2024 12:00:22 PM
- Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments • GlobeNewswire Inc. • 03/28/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:30:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 12:00:14 PM
- Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program • GlobeNewswire Inc. • 03/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 06:45:43 PM
- Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial • GlobeNewswire Inc. • 02/27/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 11:59:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:00:22 PM
- Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 01:00:15 PM
- Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:39:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:36:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 12:00:13 PM
- Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments • GlobeNewswire Inc. • 11/09/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2023 11:00:14 AM
- Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting • GlobeNewswire Inc. • 11/01/2023 11:00:00 AM
- Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference • GlobeNewswire Inc. • 10/10/2023 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 11:37:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 11:30:33 PM
- Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2023 11:00:00 AM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM